136 related articles for article (PubMed ID: 37702406)
1. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study.
Ho RS; Launonen A
J Med Econ; 2023; 26(1):1178-1189. PubMed ID: 37702406
[TBL] [Abstract][Full Text] [Related]
2. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
[TBL] [Abstract][Full Text] [Related]
5. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
[TBL] [Abstract][Full Text] [Related]
6. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song Y; Tilly H; Rai S; Zhang H; Jin J; Goto H; Terui Y; Shin HJ; Kim WS; Cao J; Feng J; Eom HS; Kim TM; Tsai XC; Gau JP; Koh H; Zhang L; Song Y; Yang Y; Li W; Huang H; Ando K; Sharman JP; Sehn LH; Bu L; Wang X; Jiang Y; Hirata J; Lee C; Zhu J; Izutsu K
Blood; 2023 Apr; 141(16):1971-1981. PubMed ID: 36626583
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
[TBL] [Abstract][Full Text] [Related]
8. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
Spinner MA; Advani RH
Oncology (Williston Park); 2022 Jan; 36(1):51-58. PubMed ID: 35089671
[TBL] [Abstract][Full Text] [Related]
9. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
10. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma.
Harris W; Bataillard EJ; Choi Y; El-Galaly TC; Cuchelkar V; Henneges C; Kwan A; Schneider DJ; Paulson JN; Nielsen TG
JCO Clin Cancer Inform; 2022 Jan; 6():e2100121. PubMed ID: 35044836
[TBL] [Abstract][Full Text] [Related]
11. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
12. Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.
Sheng Z; Li D; Chen B; Zhao C; Zhang W; Ding B; Wang L
Ann Hematol; 2023 May; 102(5):1011-1017. PubMed ID: 36947214
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
14. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
Villacampa G; Dienstmann R; Bosch F; Abrisqueta P
Ann Hematol; 2021 Dec; 100(12):2969-2978. PubMed ID: 34378095
[TBL] [Abstract][Full Text] [Related]
15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
16. Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
Liang Y; Liu X; Yang J; Wang H; Piao Y; Wei L; Wang L
Chin Med J (Engl); 2023 Jan; 136(2):167-175. PubMed ID: 36780421
[TBL] [Abstract][Full Text] [Related]
17. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
Davis JA; Shockley A; Herbst A; Hendrickson L
J Adv Pract Oncol; 2023 Jan; 14(1):67-72. PubMed ID: 36741209
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
Ohmachi K; Kinoshita T; Tobinai K; Ogawa G; Mizutani T; Yamauchi N; Fukuhara N; Uchida T; Yamamoto K; Miyazaki K; Tsukamoto N; Iida S; Utsumi T; Yoshida I; Imaizumi Y; Tokunaga T; Yoshida S; Masaki Y; Murayama T; Yakushijin Y; Suehiro Y; Nosaka K; Dobashi N; Kuroda J; Takamatsu Y; Maruyama D; Ando K; Ishizawa K; Ogura M; Yoshino T; Hotta T; Tsukasaki K; Nagai H;
Blood Adv; 2021 Feb; 5(4):984-993. PubMed ID: 33591324
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Samineni D; Huang W; Gibiansky L; Ding H; Zhang R; Li C; Sinha A; Rajwanshi R; Humphrey K; Bazeos A; Salem AH; Miles D
Adv Ther; 2022 Jan; 39(1):598-618. PubMed ID: 34822104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
